Table 6

Multivariate-adjusteda ORs and 95% CIs for breast cancer in relation to lipid-adjustedb log-transformed serum levels of organochlorine compounds stratified by age, menopausal status, and years of residence on Long Island among breast cancer cases and controls, Long Island Breast Cancer Study Project, 1996–1997

CovariateOrganochlorine compoundTertile cutpoints (ng/g lipid)Cases, nControls, nMultivariate-adjusteda
OR(95% CI)
Age at reference date
 <65 yearsDDE<458.251771291.00
458.26–951.821381130.86(0.60–1.23)
951.83–11,818.78106781.15(0.75–1.76)
Peak-4 PCBs<308.341791291.00
308.35–472.451371080.92(0.65–1.31)
462.46–3,287.34104791.08(0.72–1.61)
Chlordane<79.181491131.00
79.19–125.531401021.08(0.75–1.56)
125.54–473.08100830.96(0.63–1.45)
 65+ yearsDDE<458.2525101.00
458.26–951.8249260.81(0.34–1.98)
951.83–11,818.78128610.91(0.40–2.06)
Peak-4 PCBs<308.343691.00
308.35–472.4554290.42(0.17–1.01)
462.46–3,287.34108590.42(0.19–0.96)
Chlordane<79.1830161.00
79.19–125.5346260.95(0.44–2.06)
125.54–473.08113481.26(0.62–2.56)
Menopausal status
 PremenopausalDDE<458.25110751.00
458.26–951.8272480.95(0.57–1.57)
951.83–11,818.7830230.86(0.44–1.71)
Peak-4 PCBs<308.34101731.00
308.35–472.4573431.22(0.74–2.03)
462.46–3,287.3436270.94(0.51–1.74)
Chlordane<79.1891711.00
79.19–125.5368421.35(0.80–2.28)
125.54–473.0832221.11(0.56–2.17)
 PostmenopausalDDE<458.2585551.00
458.26–951.82115850.81(0.52–1.27)
951.83–11,818.78991121.10(0.70–1.74)
Peak-4 PCBs<308.34109551.00
308.35–472.45113870.59(0.38–0.92)
462.46–3,287.341741090.73(0.47–1.12)
Chlordane<79.1885551.00
79.19–125.53112780.92(0.59–1.46)
125.54–473.08791011.09(0.70–1.69)
Years of residence on Long Island
 <15 yearsDDE<458.2531281.00
458.26–951.8231191.47(0.66–3.28)
951.83–11,818.7840192.13(0.81–5.60)
Peak-4 PCBs<308.3435271.00
308.35–472.4532231.09(0.51–2.34)
462.46–3,287.3434161.52(0.64–3.62)
Chlordane<79.1837231.00
79.19–125.5329220.70(0.31–1.55)
125.54–473.0829141.12(0.46–2.73)
 15+ yearsDDE<458.251711111.00
458.26–951.821561200.76(0.53–1.08)
951.83–11,818.781941200.94(0.64–1.38)
Peak-4 PCBs<308.341791111.00
308.35–472.451591140.80(0.56–1.13)
462.46–3,287.341781220.83(0.58–1.20)
Chlordane<79.181421061.00
79.19–125.531571061.09(0.76–1.56)
125.54–473.081831171.06(0.73–1.56)
  • a DDE and Peak-4 PCB analyses were adjusted for age, race, history of fertility problems, and history of benign breast disease. Chlordane analyses were adjusted for age, race, history of fertility problems, and gravidity.

  • b Adjusted using method 2 as described by Phillips et al. (50) .